0001730463false2026Q112/3100-0000000Truehttp://fasb.org/us-gaap/2025#ProductMemberhttp://fasb.org/us-gaap/2025#ProductMember11P3YP4YP2Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:GBPxbrli:sharesautl:segmentautl:securityiso4217:GBPautl:votexbrli:pureautl:paymentautl:batchiso4217:EURautl:director00017304632026-01-012026-03-310001730463dei:AdrMember2026-01-012026-03-310001730463autl:OrdinarySharesMember2026-01-012026-03-3100017304632026-05-1300017304632026-03-3100017304632025-12-310001730463autl:OrdinarySharesMember2025-12-310001730463autl:OrdinarySharesMember2026-03-310001730463autl:DeferredSharesMember2025-12-310001730463autl:DeferredSharesMember2026-03-310001730463autl:DeferredClassBSharesMember2026-03-310001730463autl:DeferredClassBSharesMember2025-12-310001730463autl:DeferredClassCSharesMember2026-03-310001730463autl:DeferredClassCSharesMember2025-12-3100017304632025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2025-12-310001730463us-gaap:AdditionalPaidInCapitalMember2025-12-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001730463us-gaap:RetainedEarningsMember2025-12-310001730463us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001730463us-gaap:RetainedEarningsMember2026-01-012026-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2026-03-310001730463us-gaap:AdditionalPaidInCapitalMember2026-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001730463us-gaap:RetainedEarningsMember2026-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2024-12-310001730463us-gaap:AdditionalPaidInCapitalMember2024-12-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001730463us-gaap:RetainedEarningsMember2024-12-3100017304632024-12-310001730463us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-01-012025-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001730463us-gaap:RetainedEarningsMember2025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2025-03-310001730463us-gaap:AdditionalPaidInCapitalMember2025-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001730463us-gaap:RetainedEarningsMember2025-03-3100017304632025-03-310001730463autl:RebatesMember2025-12-310001730463autl:ChargebackMember2025-12-310001730463autl:RebatesMember2026-01-012026-03-310001730463autl:ChargebackMember2026-01-012026-03-310001730463autl:RebatesMember2026-03-310001730463autl:ChargebackMember2026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001730463us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001730463us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001730463us-gaap:WarrantMember2026-01-012026-03-310001730463us-gaap:WarrantMember2025-01-012025-03-310001730463us-gaap:MoneyMarketFundsMember2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CommercialPaperMember2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CommercialPaperMember2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMember2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMember2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:MoneyMarketFundsMember2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CommercialPaperMember2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMember2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CommercialPaperMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:CommercialPaperMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:EquipmentMember2026-03-310001730463us-gaap:EquipmentMember2025-12-310001730463us-gaap:OfficeEquipmentMember2026-03-310001730463us-gaap:OfficeEquipmentMember2025-12-310001730463us-gaap:FurnitureAndFixturesMember2026-03-310001730463us-gaap:FurnitureAndFixturesMember2025-12-310001730463us-gaap:LeaseholdImprovementsMember2026-03-310001730463us-gaap:LeaseholdImprovementsMember2025-12-310001730463us-gaap:AssetUnderConstructionMember2026-03-310001730463us-gaap:AssetUnderConstructionMember2025-12-310001730463autl:UCLBusinessplcMemberus-gaap:IntellectualPropertyMember2025-07-012025-09-300001730463us-gaap:RestrictedStockUnitsRSUMember2026-03-310001730463us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2026-04-012026-05-140001730463autl:A2025EmployeeSharePurchasePlanMember2025-05-310001730463autl:A2025InducementPlanMember2025-03-270001730463autl:A2025InducementPlanMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001730463us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001730463us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001730463us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001730463us-gaap:CostOfSalesMember2026-01-012026-03-310001730463us-gaap:CostOfSalesMember2025-01-012025-03-3100017304632025-01-012025-12-310001730463us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2025-12-310001730463us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463autl:BlackstoneMember2021-11-012021-11-300001730463autl:BlackstoneMember2022-12-012022-12-310001730463autl:BlackstoneMember2022-12-310001730463autl:BlackstoneMember2024-11-080001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-062024-02-060001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-060001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-012024-02-290001730463autl:BlackstoneMember2026-03-310001730463autl:BlackstoneMember2025-03-310001730463autl:BioNTechMember2026-03-310001730463autl:BioNTechMember2025-03-310001730463autl:UCLBusinessplcMember2026-01-012026-03-310001730463us-gaap:CapitalAdditionsMember2026-03-310001730463autl:ReagentsAndDisposablesMember2026-03-3100017304632026-01-212026-01-2100017304632023-01-012023-12-310001730463autl:ReportableSegmentMember2026-01-012026-03-310001730463autl:ReportableSegmentMember2025-01-012025-03-310001730463autl:BlackstoneMemberautl:AutolusMember2021-11-3000017304632021-11-300001730463autl:BlackstoneMemberautl:AutolusMember2026-03-310001730463autl:BlackstoneMember2026-01-012026-03-310001730463autl:BlackstoneMember2025-12-310001730463autl:BioNTechMemberautl:AutolusMember2026-03-310001730463autl:BioNTechMember2026-01-012026-03-310001730463autl:BioNTechMember2025-12-310001730463srt:ScenarioForecastMember2025-07-012026-09-300001730463us-gaap:SubsequentEventMember2026-04-29

Commission File Number 001-38547

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, par value $0.000042 per share			AUTL			The Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share*			*			The Nasdaq Stock Market LLC*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “an emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of May 13, 2026, the registrant had 266,155,786 ordinary shares (including shares in form of American Depositary Shares (“ADSs”)), par value $0.000042 per share, outstanding.

Autolus Therapeutics plc (the “Company”) qualifies as a “Foreign Private Issuer,” as defined in Rule 3b-4 under the Securities Exchange Act of 1934 (the “Exchange Act”) and is exempt from filing quarterly reports on Form 10-Q by virtue of Rules 13a-13 and 15d-13 under the Exchange Act. The Company has voluntarily elected to file this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Accordingly, as a foreign private issuer, the Company remains exempt from the U.S. federal proxy rules pursuant to Section 14 of the Exchange Act and Regulations 14A and 14C thereunder, Regulation FD, and its officers, directors, and principal shareholders are not subject to the short-swing profit disclosure and recovery provisions contained in Section 16 of the Exchange Act.

Unless context otherwise requires, all references in this Quarterly Report on Form 10-Q to “Autolus,” the “Group,” the “company,” “we,” “us” and “our” refer to Autolus Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires.

Autolus, AUCATZYL® and our other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are our property. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Quarterly Report on Form 10-Q may be trademarks, trade names or service marks of their respective owners.

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

•the therapeutic potential and expected clinical benefits of AUCATZYL/obe-cel (obecabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (“r/r B-ALL”);

•our ability to generate revenues from AUCATZYL, which is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors;

•our ability to maintain regulatory approval of AUCATZYL in the US, European Union (“EU”) and United Kingdom (“U.K.”), to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof, and to obtain and maintain regulatory approval of our other product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;

•our expectations regarding the commercialization and marketing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories;

•the development of our commercial product and product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;

•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

•our commercialization, marketing and manufacturing capabilities and strategy for AUCATZYL, including our ability to successfully recruit and retain sales and marketing personnel and to successfully build the market for AUCATZYL;

•our expectations about the willingness of healthcare providers to recommend AUCATZYL to people with adult r/r B-ALL;

•the impacts of public health crises and their effects on our operations and business, including interruption of key clinical trial activities, such as clinical trial site monitoring, access to capital, and potential disruption in the operations and business of third-party manufacturers, clinical sites, contract research organizations (“CROs”), other service providers and collaborators with whom we conduct business;

•our expectations regarding our ability to obtain and maintain intellectual property protection and our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements;

•our plans to research, develop, manufacture and commercialize our product candidates;

•the potential benefits of our commercial product and product candidates;

•the timing or likelihood of regulatory filings and approvals for our product candidates, along with regulatory developments in the US, EU, U.K. and other foreign countries;

•the size and growth potential of the markets for our commercial product and product candidates, if approved, and the rate and degree of market acceptance of our commercial product and product candidates, including reimbursement that may be received from payors;

•our need for and ability to obtain additional funding, on favorable terms or at all;

•our plans to collaborate, or statements regarding our current collaborations with BioNTech SE (“BioNTech”) and others;

•our license and option agreement with BioNTech (the “BioNTech License and Option Agreement”), including our potential to receive milestone payments and royalties under the agreement;

•our ability to attract collaborators with development, regulatory and commercialization expertise;

•our ability to identify, recruit and retain qualified employees and key personnel;

•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•the scalability and commercial viability of our manufacturing methods and processes;

•the success of competing therapies that are or may become available;

•whether we are classified as a Passive Foreign Investment Company (“PFIC”), for current and future periods;

•additional costs and expenses related to our decision to voluntarily comply with certain U.S. domestic issuer reporting obligations before we are required to do so; and

•any other factors which may impact our financial results or future trading prices of our ADSs, and the impact of securities analysts’ reports on these prices.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known and unknown risks, uncertainties and other factors including, without limitation, risks, uncertainties and assumptions regarding the impact of macroeconomic events, including inflation, changes in interest rates, tariffs, changes in trade policies, political changes, general market conditions and the impacts of the war in Ukraine, conflicts in the Middle East and Europe, and global geopolitical tensions, on our business, operations, strategy, goals and anticipated timelines, our ongoing and planned preclinical activities, our ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, our timelines for regulatory submissions and our financial position that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Except as required by law, we do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances.

(In thousands, except share and per share amounts)

(Unaudited, in thousands, except share and per share amounts)

(Unaudited, in thousands, except share amounts)

(Unaudited, in thousands)

(Unaudited, in thousands)

			Three Months Ended March 31,
			2026						2025
Unaudited supplemental cash flow information
Cash paid for income taxes			$	209					$	9
Unaudited supplemental non-cash flow information
Property and equipment purchases included in accounts payable or accrued expenses			$	145					$	2,279
Leased assets obtained in exchange for operating lease liabilities			$	9,123					$	71
Capitalized share-based compensation, net of forfeitures			$	1					$	9
Capitalized implementation costs included in accounts payable and accrued expenses			$	137					$	289
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:
Cash and cash equivalents			$	130,925					$	95,799
Restricted cash			1,493						1,452
Total cash, cash equivalents and restricted cash			$	132,418					$	97,251

Autolus Therapeutics plc (with its subsidiaries, collectively, “Autolus” or the “Company”) is a commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in- class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

On November 8, 2024 Autolus was notified by the United States Food and Drug Administration (the “FDA”) that its biologics license application (“BLA”) was approved, allowing for the marketing of AUCATZYL (obecabtagene autoleucel, also known as obe-cel) in the United States for the treatment of adult patients (18 years and older) with r/r B-ALL. The first sale of AUCATZYL in the United States occurred in January 2025.

The United Kingdom Medicines and Healthcare products Regulatory Agency granted AUCATZYL conditional marketing authorization in April 2025. In November 2025, the National Institute for Health and Care Excellence recommended AUCATZYL for use in the National Health Service (“NHS”) in England and Wales as a treatment option for adult patients (age 26 and older) with r/r B-ALL. We launched AUCATZYL in the United Kingdom in January 2026, and it is available through routine commissioning by the NHS.

In July 2025, the European Commission granted marketing authorization for AUCATZYL in adult patients (age 26 and older) with r/r B-ALL. Evaluation of potential pricing and feasibility of market entry opportunities in certain EU countries is ongoing. At this time, the EU launch, including launch in Germany, is on hold. The Company did not generate any EU product revenue of AUCATZYL in 2025 and does not anticipate any EU product revenue in 2026.

Autolus is registered in England and Wales. Its registered office is The MediaWorks, 191 Wood Lane, London, W12 7FP, United Kingdom.

The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company’s product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. The Company also expects to incur significant additional costs as it expands its commercialization efforts for AUCATZYL. These efforts will require significant amounts of capital, as well as additional personnel, infrastructure, and compliance capabilities. Even if the Company’s product development efforts for obe-cel and its other product candidates are successful, it is uncertain when, if ever, the Company will become profitable.

The Company is a public limited company incorporated under the laws of England and Wales, and qualifies as a “foreign private issuer,” as such term is defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 3b-4 under the Exchange Act, and, therefore, is not subject to the same requirements that are imposed upon United States domestic issuers by the Securities and Exchange Commission (the “SEC”). The Company has decided to voluntarily file periodic reports, such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K on United States domestic issuer forms, which are more detailed and extensive in certain respects, and which must be filed more promptly than the forms currently required for foreign private issuers. Although the Company has voluntarily chosen to file periodic reports and current reports on United States domestic issuer forms, the Company has maintained its status as a foreign private issuer and is not subject to certain other requirements imposed on United States domestic issuers.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and are presented in US dollars. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

The condensed consolidated balance sheet at December 31, 2025, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

The significant accounting policies used in the preparation of these unaudited condensed consolidated interim financial statements are consistent with those discussed in Note 2, “Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 27, 2026 (the “Annual Report”). The information included in these unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2025, included in the Annual Report.

These unaudited condensed consolidated interim financial statements include all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary to fairly state the Company’s financial position as of March 31, 2026, and the results of its operation for the three-month period ended March 31, 2026, and cash flows for the three-month period ended March 31, 2026. The interim results and cash flows are not necessarily indicative of results and cash flows that may be expected for the year ending December 31, 2026.

In accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Going Concern, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

The Company has incurred recurring losses since its inception, including net losses of $71.6 million and $70.2 million for the three months ended March 31, 2026 and 2025, respectively. The Company had an accumulated deficit of $1,458.4 million and $1,386.8 million as of March 31, 2026 and December 31, 2025, respectively.

Notwithstanding these conditions, based on its cash and cash equivalents and marketable securities of $130.9 million and $98.5 million, respectively, as of March 31, 2026, together with its forecasted operating plan, the Company expects that its existing financial resources will be sufficient to fund its operations for at least one year from the date these condensed consolidated financial statements are issued. Accordingly, management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.

In performing this assessment, the Company prepared cash flow forecasts for the one-year period from the date of issuance, which reflect management’s current operating plan and expectations. These forecasts include assumptions regarding increases in product revenues and gross margin, cost reductions resulting from the restructuring actions announced in April 2026, and expected timing of cash inflows from R&D tax credits, including the R&D tax credit claimed by the Company in its corporate tax return for the accounting period to December 2023 that is subject to ongoing discussions with the United Kingdom tax authority. These assumptions are subject to uncertainty due to numerous factors, including the Company’s limited sales history following its recent product launches in the U.S. and U.K., it’s ability to obtain cost reductions, and other factors outside the Company’s control. While management believes these assumptions are reasonable, actual results may differ, and the Company may use its cash resources sooner than currently expected.

The Company has historically funded its operations primarily through the issuance of equity securities, licensing and collaboration arrangements, and other strategic financing transactions. The Company expects to continue to incur losses for the foreseeable future as it advances the development, approval, and commercialization of its product candidates. While the Company may require additional capital to support its operating plans and achieve profitability, such funding is not expected to be required to meet its obligations as they become due within one year from the date these condensed consolidated financial statements are issued.

The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated interim financial statements include, but are not limited to, the accrual for research and development expenses, income taxes and present value of liabilities related to future royalties and milestones, net including the related interest expense and cumulative catch-up adjustment, incremental borrowing rates related to the Company’s leased properties, and the estimated expected rebate and chargeback percentage for revenue deductions related to product revenue, net. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.

The Company’s Executive Committee, which includes its Chief Executive Officer, is its chief operating decision maker (the “CODM”). The CODM manages the Company’s operations on an integrated basis for the purpose of appropriately allocating resources. When evaluating the Company’s financial performance, the CODM reviews total revenue, total expenses and expenses by function and makes decisions using this information on a global basis. The Company and the CODM view the Company’s operations and manage its business as a single operating and reportable segment, which is the business of developing and commercializing CAR T therapies.

During the three-month period ended March 31, 2025, the Company’s product revenue, net was solely comprised of sales of AUCATZYL in the U.S. The Company uses Cardinal Health 105, LLC (“Cardinal Health”) as an agent to deliver the Company’s product, AUCATZYL, to Authorized Treatment Centers (“ATC”). The ATCs are responsible for the treatment of the patient including infusion of the product which occurs in two separate doses. Cardinal Health is obligated to pay the Company for the product upon the delivery and acceptance of the product at the ATC within standard payment terms. The ATC is obligated to pay Cardinal Health for the product upon receipt and acceptance of the product and is entitled to a credit in certain circumstances, including when the patient is not administered one or both doses.

During the three-months ended March 31, 2026, the Company launched AUCATZYL in the U.K. Consequently, the Company's product revenue, net now includes sales of AUCATZYL in the U.S. and U.K. AUCATZYL is available through the National Health Service (“NHS”) and private treatment centers.

The Company accounts for product revenues pursuant to the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.

The Company has determined that the patient is the customer in the arrangement pursuant to ASC 606. The Company has identified a single performance obligation, which is satisfied when the patient has received its second (final) dose of the product, and it records an accounts receivable on the balance sheet when product sales are invoiced and the final dose of the product has been administered to the patient.

Product revenue, net of gross-to-net deductions, is recognized only to the extent that a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. In the United States, product revenue is recognized net of estimated rebates and chargebacks, patient travel assistance and patient co-pay assistance deductions. These deductions to product revenue are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product revenue occurs. Currently there are no such deductions for sales outside of the United States.

Rebates and chargebacks

Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payors and healthcare providers under various programs. These amounts may vary by payor and individual plans. Providers qualified under certain programs can purchase the Company’s products through the Company’s third-party logistics partner at a discount. The Company’s third-party logistics partner then charge the discount back to the Company.

In the United States, rebates and chargebacks are estimated primarily based on product sales, including pricing, historical and estimated payor mix, setting of care and discount rates, among other inputs, which require significant estimates and judgment. The Company assesses and updates its estimates each reporting period to reflect actual claims and other current information.

In the United States, the chargebacks the Company participates in for covered entities under the 340B Program, the Department of Defense (DoD), and the Department of Veteran Affairs (VA), whereby pricing on products is extended below list price to participating entities. These entities purchase products at the lower program price then charge the Company the difference between their acquisition cost and the lower program price. The price differential is accrued for as part of the gross to net liabilities and will be reflected as a reduction to accounts receivable, net when actual chargeback is processed and applied. Currently there are no such chargebacks for sales outside of the United States.

In the United States, the rebates the Company participates in are state government Medicaid programs and the TriCare program. All discounts and rebates provided through these programs are included in the Company’s Medicaid and TriCare rebate accrual. The estimated amount of unpaid or unbilled rebates are recognized and presented as a liability. Currently there are no such rebates for sales outside of the United States.

The Company may provide co-pay or other financial assistance to patients, such as travel and lodging reimbursement, which are treated as consideration payable to a customer and recorded as a reduction to product sales based on an estimate of the amounts to be paid at the time revenue is recognized.

The reporting currency of the Company is in U.S. dollars. The Company has determined that its functional currency of the ultimate parent company, Autolus Therapeutics plc, is British Pound Sterling. The functional currency of each subsidiary’s operations is the applicable local currency. Monetary assets and liabilities denominated in currencies other than the Company’s functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Translation adjustments are not included in determining net income (loss) but are included in foreign currency translation to other comprehensive loss, a component of shareholders’ equity.

The Company recorded foreign exchange losses of $2.7 million and foreign exchange gains of $1.2 million for the three months ended March 31, 2026 and 2025, respectively, which are included in foreign exchange (losses) gains, net in the unaudited condensed consolidated statements of operations and comprehensive loss.

In November 2024, the FASB issued ASU 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to improve the disclosures about entity’s expenses. The amendments apply to all public business entities. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted.

The Company is currently evaluating the impact this new accounting will have on its consolidated financial statements and disclosures In July 2025, the FASB issued ASU 2025-05—Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets to provide all entities with a practical expedient and entities other than public business entities with an accounting policy election when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606. The ASU is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The adoption of ASU 2025-05 in the current period has not had a material effect on the Company’s consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software to remove all references to prescriptive and sequential software development stages (referred to as “project stages”) throughout Subtopic 350-40. The ASU is effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact this new accounting will have on its consolidated financial statements and disclosures

In December 2025, the Financial Accounting Standards Board (the “FASB”) issued the Accounting Standards Update (“ASU”) 2025-12, Codification Improvements that represent changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. The amendments make the Codification easier to understand and apply. The ASU is effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. This ASU is not expected to have a material effect on the Company’s consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements to clarify interim disclosure requirements and the applicability of Topic 270, Interim Reporting. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for entities other than public business entities. The Company is currently evaluating the impact this new accounting will have on its consolidated financial statements and disclosures

On November 8, 2024, the Company was notified by the FDA that the Company’s BLA was approved, allowing for the marketing of AUCATZYL in the United States for the treatment of adult patients with r/r B-ALL. The first sale of AUCATZYL in the United States occurred in January 2025. In November 2025, the NICE recommended AUCATZYL for use in the NHS in England and Wales as a treatment option for adult patients (age 26 and older) with r/r B-ALL. The first sale of AUCATZYL in the United Kingdom occurred in January 2026.

Product revenue, net recognized after estimated deductions for rebates and chargebacks for the three months ended March 31, 2026, and 2025 (in thousands):

Accounts receivable, net as of March 31, 2026 and December 31, 2025 was $27.7 million and $24.0 million, respectively. An allowance for lifetime expected credit losses on accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability. Expected credit losses as of March 31, 2026 and December 31, 2025, based on the Company's third-party agreements are immaterial.

Current accruals for rebates and chargebacks as of March 31, 2026 were as follows (in thousands):

Interest expense, net consisted of the following (in thousands):

Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):

For all periods presented, outstanding but unvested RSUs, share options and warrants have been excluded from the calculation as their effects would be anti-dilutive. Therefore, the weighted average number of ordinary shares used to calculate both basic and diluted loss per share are the same for all periods presented.

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in the following levels:

• Level 1 — Quoted prices in active markets for identical assets or liabilities.

• Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

• Level 3 — Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.

The carrying amounts reported in the balance sheet for cash and cash equivalents, restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):

The Company estimates the fair value of available-for-sale debt securities using actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observable market prices are not available (such as for securities with short maturities and limited second market activity), the securities are priced using a valuation model that maximizes the use of observable inputs, such as market interest rates.

As of March 31, 2026 and December 31, 2025, the Company did not have non-financial assets measured at fair value on a recurring basis. During the three months ended March 31, 2026 and the year ended December 31, 2025, there were no transfers between fair value levels.

As of March 31, 2026 and December 31, 2025, the Company has the following investments in available-for-sale debt securities, which are categorized as marketable securities: available-for-sale debt securities on the balance sheet depending on their maturity at acquisition (in thousands):

The number of securities held by the Company and aggregate fair value (in thousands) and in an unrealized loss position as of March 31, 2026 and December 31, 2025 are as follows (in thousands):

The aggregated net unrealized loss on available-for-sale debt securities in the amount of $0.1 million has been recognized in accumulated other comprehensive loss in the Company’s condensed consolidated balance sheet as of March 31, 2026.

At March 31, 2026, the Company held 14 marketable securities: available-for-sale debt securities out of its total investment portfolio that were in a continuous unrealized loss position. As of March 31, 2026, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position. The related unrealized losses are not severe, have been for a short duration and are due to normal market, exchange rate fluctuations and all securities have an investment-grade credit rating. The Company neither intends to sell these investments nor has concluded that it will more-likely-than-not have to sell them before recovery of their carrying values. The Company also believes that it will be able to collect both principal and interest amounts due to the Company at maturity.

There were no amounts reclassified out of other comprehensive income (loss), net of tax during the three months ended March 31, 2026 and during the year ended December 31, 2025.

Inventories, net consisted of the following (in thousands):

						March 31,						December 31,
						2026						2025
Raw materials						$	12,590					$	16,160
Consumables						6,843						8,021
Work in progress						6,255						3,633
Finished goods						7,545						5,395
Total inventories, net						$	33,233					$	33,209

Inventory write-downs as a result of excess, obsolescence, scrap or other reasons are recorded in cost of sales in the Company’s consolidated statements of operations. For the three months ended March 31, 2026 and 2025, inventory write-downs were $2.0 million and nil, respectively. Inventory write-downs were mainly related to inventory in excess of expected demand and shelf-life expiration. Inventory amounts above are net of the associated inventory write-downs.

Prepaid expenses and other current assets consisted of the following (in thousands):

Property and equipment, net consisted of the following (in thousands):

Depreciation expense for the three months ended March 31, 2026 and 2025 was $2.2 million and $1.9 million, respectively.

The following table summarizes the carrying amount of the Company's intangible assets, net of accumulated amortization (in thousands):

						March 31,						December 31,
						2026						2025
Licensed IP rights						$	21,145					$	21,528
Less: accumulated amortization						(2,169)						(1,719)
Total intangibles assets, net						$	18,976					$	19,809

Amortization expense for the three months ended March 31, 2026 and 2025 was $0.5 million and $0.3 million, respectively. The estimated annual amortization expense related to this asset is $1.9 million for each of the five years ending in 2031.

On July 18, 2025, the Company was notified by the European Commission that the Company has been granted marketing approval for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients (26 years and older) with r/r B-ALL, which triggered a £6.0 million regulatory milestone payment that was paid by the Company to UCL Business Ltd (“UCLB”) in the third quarter of 2025, pursuant to a certain exclusive license agreement, as amended (the “UCLB License Agreement”). This milestone payment was capitalized as an intangible assets and amortized over the remaining useful life of the patent.

Accrued expenses and other liabilities consisted of the following (in thousands):

Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the Company’s board of directors and declared by the shareholders. As of March 31, 2026, the Company has not declared any dividends.

At March 31, 2026, restricted stock unit awards for 12,500 ordinary shares had vested but the underlying shares had not been issued. However, these vested restricted stock unit awards have been included in the calculation of the Company’s outstanding shares at March 31, 2026 as they are considered issuable for little or no cash consideration. Subsequent to March 31, 2026, 12,500 of the underlying ordinary shares will be issued.

In May 2025, the Company’s board of directors adopted the 2025 Employee Share Purchase Plan (the “Purchase Plan” or “ESPP”), which became effective upon approval by the Company’s shareholders in June 2025. The following description of the Purchase Plan is a summary only and is qualified in its entirety by reference to the complete text of the Purchase Plan. Subject to adjustment for certain changes in the Company’s capitalization, the maximum number of Shares (as defined therein) that may be issued under the Purchase Plan is 3,000,000. The Purchase Plan includes both (i) a 423 Component (as defined therein), which is intended to be used to grant rights to purchase Shares which qualify as options issued under an “employee stock purchase plan” as that term is defined in Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and (ii) a Non-423 Component (as defined therein), which is intended to be used to grant rights to purchase Shares which do not qualify for such treatment under the Code. The UK Sharesave Sub-Plan has been adopted as a sub-plan to the Purchase Plan. The Sharesave is a UK “all employee” share option plan, which is intended to satisfy the requirements of Schedule 3 of ITEPA for tax qualifying save-as-you-earn share options plans. The Purchase Plan, including any sub-plans, is administered by the Company’s board of directors, which may delegate such administration to a committee comprised of one or more members of the board. The plan administrator has the power, subject to the provisions of the Purchase Plan, to determine when and how rights to purchase the Company’s shares will be granted, the provisions of each offering of such rights (which need not be identical), and whether employees of any of Autolus parent or subsidiary companies will be eligible to participate in the Purchase Plan. The Company has not yet initiated any purchase periods or granted shares under the ESPP as of March 31, 2026.

The Company’s 2025 Inducement Plan (the “2025 Inducement Plan”) became effective on March 27, 2025 and, in accordance with Nasdaq listing rules and the SEC requirements, provides for issuance of inducement equity awards to qualifying individuals in connection with their entering into employment with the Company or its affiliates. Awards granted under the 2025 Inducement Plan will not exceed 3,000,000 ADSs, representing an equal number of ordinary shares. Equity awards granted under the 2025 Inducement Plan generally vest in the same manner as other Company share option awards, with 25% of the share option awards vesting one year after the vesting commencement date and the remainder of the awards vesting in equal monthly installments over three additional years. Restricted share unit awards under the 2025 Inducement Plan generally vest in four equal annual installments.

The following table summarizes the total share-based compensation expense included in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):

The table below summarizes Company’s share option activity during the three months ended March 31, 2026:

The weighted average grant-date fair value of share options granted was $1.09 per share option for the three months ended March 31, 2026. The weighted average grant-date fair value of share options granted was $1.34 per share option for the three months ended March 31, 2025.

The total intrinsic value of share options exercised was nil for the three months ended March 31, 2026 and 2025, respectively.

As of March 31, 2026, the total unrecognized compensation expense related to unvested share options was $16.0 million, which the Company expects to recognize over a weighted average vesting period of 3.22 years.

The table below summarizes Company’s restricted stock unit (“RSU”) awards activity during the three months ended March 31, 2026:

As of March 31, 2026, there was $6.1 million of unrecognized share-based compensation expense related to unvested RSUs which is expected to be recognized over a weighted average period of 3.90 years.

The following table summarizes the carrying amount of the Company’s liabilities related to future royalties and milestones, net (in thousands):